Original Article

Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study

Qiu-Yan Chen, MD, PhD[1,2]
Qing-Nan Tang, MD[1,2]
Lin-Quan Tang, MD, PhD[1,2]
Wen-Hui Chen, MD, PhD[3]
Shan-Shan Guo, MD[1,2]
Li-Ting Liu, MD[1,2]
Chao-Feng Li, MD[1,4]
Yang Li, MD[1,2]
Yu-Jing Liang, MD[1,2]
Xue-Song Sun, MD[1,2]
Ling Guo, MD[1,2]
Hao-Yuan Mo, MD[1,2]
Rui Sun, MD, PhD[1,2]
Dong-Hua Luo, MD, PhD[1,2]
Yu-Ying Fan, MD[1,2]
Yan He, MD[1,2]
Ming-Yuan Chen, MD, PhD[1,2]
Ka-Jia Cao, MD[1,2]
Chao-Nan Qian, MD, PhD[1,2]
Xiang Guo, MD, PhD[1,2]
Hai-Qiang Mai, MD, PhD[1,2]

A list author's affiliations appears at the end of the paper.

Purpose

The measuring Epstein-Barr virus (EBV) DNA is an important predictor of nasopharyngeal carcinoma (NPC). This study evaluated the predictive value of pretreatment serum amyloid A (SAA) and C-reactive protein (CRP) comparing with EBV DNA in patients with NPC.

Materials and Methods

In an observational study of 419 non-metastatic NPC patients, we prospectively evaluated the prognostic effects of pretreatment SAA, CRP, and EBV DNA on survival. The primary endpoint was progress-free survival (PFS).

Results

The median level of SAA and CRP was 4.28 mg/L and 1.88 mg/L, respectively. For the high-SAA group (> 4.28 mg/L) versus the low-SAA (≤ 4.28 mg/L) group and the high-CRP group (> 1.88 mg/L) versus the low-CRP (≤ 1.88 mg/L) group, the 5-year PFS was 64.5% versus 73.1% (p=0.013) and 65.2% versus 73.3% (p=0.064), respectively. EBV DNA detection showed a superior predictive result, the 5-year PFS in the EBV DNA ≥ 1,500 copies/mL group was obviously different than the EBV DNA < 1,500 copies/mL group (62.2% versus 77.8%, p < 0.001). Multifactorial Cox regression analysis confirmed that in the PFS, the independent prognostic factors were including EBV DNA (hazard ratio [HR], 1.788; p=0.009), tumour stage (HR, 1.903; p=0.021), and node stage (HR, 1.498; p=0.049), but the SAA and CRP were not included in the independent prognostic factors.

Conclusion

The results of SAA and CRP had a certain relationship with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP were poor. However, the predictive ability of SAA and CRP was lower than that of EBV DNA.

Correspondence: Hai-Qiang Mai, MD, PhD
Department of Nasopharyngeal Carcinoma,
Sun Yat-Sen University Cancer Center,
651 Dongfeng Road East,
Guangzhou 510060, China
Tel: 86-20-87343380
Fax: 86-20-87343392
E-mail: maihq@sysucc.org.cn

*Qiu-Yan Chen, Qing-Nan Tang, and Lin-Quan Tang contributed equally to this work.

Introduction

Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia, which with a peak incidence of 50 cases per 100,000 [1]. Radiotherapy is the primary treatment modality and concurrent chemoradiotherapy with or without adjuvant chemotherapy is currently considered as the standard treatment regimen for locoregionally advanced NPC patients [2]. However, patients with similar histologic classification and stages have demonstrated remarkably different survival outcomes because of the heterogeneity of the protein expression profiles [3,4]. Various studies have attempted to discover molecular biomarkers to predict the behaviour of NPC, and numerous promising biomarkers have been evaluated as potential prognosis predictors of NPC. Among them, Epstein-Barr virus (EBV) DNA is current the best index to predict the prognosis of NPC and it is widely used in clinical application [5].

A previous study showed that chronic inflammation is a key contributor to cancer development and progression [6]. Serum amyloid A (SAA) and C-reactive protein (CRP) are both inflammatory factors and nonspecific, acute-phase, hepatic proteins secreted in response to cytokines [7]. At present, investigations have showed that SAA and CRP play important roles in the occurrence and development of tumours [8-10]. SAA is a high-density lipoprotein-associated apolipoprotein known to play a major role as a modulator of inflammation and in the metabolism and transport of cholesterol [6]. Of interest, SAA has been recently proposed as a potentially useful biomarker for gastric cancer [8] and has also been used to monitor the lymph node metastasis or relapse of nasopharyngeal cancer [9,11]. Moreover, when

using mass spectrometry and proteomic technologies in lung cancer patients, SAA was identified as the top differentially expressed protein that can differentiate the serum of patients from the serum of healthy individuals [10]. Unfortunately, only scant information regarding SAA expression in malignant human tissues has been reported thus far and, to our knowledge, no study has yet addressed SAA as a prospective biomarker of NPC. Another acute-phase serum protein, CRP, studies have shown that the high level of CRP is associated with the poor prognosis of some tumors, including breast cancer [12], and it has already been reported as a prognostic marker in NPC [13,14].

It is very necessary to use a prospective approach to verify the previous reports about SAA and CRP in the predictive function of prognosis in NPC, and compare the effect of EBV DNA. This study represents the first investigation examining pretreatment SAA and CRP and the prognosis of NPC, and compared the value EBV DNA in a large prospective cohort study. These results will provide important information for personalized therapy.

Materials and Methods

1. Patients and methods

This is a prospective cohort study. Four hundred thirty primary NPC patients were consecutively recruited from April 2007 to November 2012 at the study institute. The patients were evaluated using the seventh American Joint Committee on Cancer staging system and were eligible for this study if


Fig. 1. Cohort definition and exclusion. NPC, nasopharyngeal carcinoma; SAA, serum amyloid A; CRP, C-reactive protein; EBV, Epstein-Barr virus; PFS, progression-free survival; OS, overall survival; DMFS, distant metastasis-free survival; LRFS, locoregional relapse-free survival.

they fulfilled all of the following criteria: they had biopsy-diagnosed World Health Organization types II-III NPC, they were aged between 18 and 80 years, and they had a satisfactory performance status (a score of 0-2 using the Eastern Cooperative Oncology Group System). The exclusion criteria included previous treatment for NPC, presence of distant metastasis, or prior malignancy (except carcinoma *in situ* of the cervix or basal/squamous cell carcinoma of the skin). Firstly, there were 430 NPC patients enrolled. Subsequently, three patients lost contact, and two patients refused to radiotherapy. There were 425 patients completed SAA, CRP, and EBV DNA measurements. Then, six patients were missing to follow up after radiotherapy. Finally, 419 non-metastatic primary patients were eligible for survival analysis (Fig. 1).

All of the patients were evaluated by complete physical examination, nasopharyngoscopy, head and neck magnetic resonance imaging (MRI), abdominal sonography, electrocardiography, chest radiography, bone scan, complete blood count with a differential count, biochemical profile, and prior treatment SAA, CRP, and EBV DNA levels. ^{18}F-fluorodeoxyglucose positron emission tomography and computed tomography (PET-CT) was optional and was performed at the discretion of the attending physician. Before treatment, baseline clinical information was collected regarding sex, age, hereditary NPC, smoking status, TNM stage, and Eastern Cooperative Oncology Group (ECOG). Previous studies have indicated that some factors promoted increased plasma SAA and CRP levels, such as cardiovascular disease, diabetes, and chronic hepatitis B virus (HBV) infection. The definitions of these comorbidities and smoking status are presented in Supplementary Materials.

For these 419 patients, age 18-80 years (median age, 46 years), and 313 (74.7%) for male and 106 (25.3%) for female. The distribution of stage was as following: 10 (2.4%) for stage I, 38 (9.1%) for stage II, 235 (56.1%) for stage III, 91 (21.7%) for stage IVa, and 45 (10.7%) for stage IVb. There were 126 (30.1%) were treated with conventional two-dimensional radiotherapy or three-dimensional conformal radiotherapy, and 293 (69.9%) were treated with intensity-modulated radiotherapy. Additionally, 369 (88.1%) of these patients with stage II-IV disease received platinum-based chemotherapy. Concurrent chemoradiotherapy with or without neoadjuvant or adjuvant chemotherapy was administered for advanced-stage disease (stages III and IV). A stratified multitherapeutic protocol was used: radiation alone for stage I disease and radiation alone or concurrent platinum-based chemotherapy for stage II disease; concurrent chemoradiotherapy with or without neoadjuvant or adjuvant chemotherapy for advanced-stage disease (stages III and IV). Neoadjuvant or adjuvant chemotherapy consisted of cisplatin with 5-fluorouracil or taxane administered every 3 weeks for two or three cycles. Concurrent chemotherapy consisted of cis-platin given on weeks 1, 4, and 7 of radiotherapy or weekly cisplatin. All of the patients were treated according to the same principles of the treatment for NPC patients at the study institute.

2. Plasma SAA, CRP, and EBV DNA evaluations

Each blood sample was allowed to clot and was centrifuged at 1,500 ×g for 10 minutes. Sera were collected, aliquoted, and kept frozen at −70°C until analysis. This molecular study was approved by the Ethics Committee of the study institute. The SAA levels were measured in serum samples using commercial enzyme-linked immunosorbent assay (ELISA) kits from Invitrogen (Camarillo, CA) according to the manufacturer's instructions. All of the ELISAs were performed in duplicate. The results were obtained by a standard curve prepared according to the manufacturer's instructions and with a coefficient of variation < 10%. The plasma CRP concentrations were immunoturbidimetrically quantified using a Roche automated clinical chemistry analyzer (Roche Diagnostics, Belleville, NJ). As described in previous study [15], patient plasma EBV DNA concentrations were routinely measured by quantitative polymerase chain reaction before treatment.

3. Clinical outcome assessment and patient follow-up

Our primary endpoint was progress-free survival (PFS), and the secondary endpoints were overall survival (OS), distant metastasis-free survival (DMFS), and local-regional recurrence-free survival (LRFS). The definitions of these endpoints are presented in the Supplementary Materials. After treatment was completed, patients were evaluated at 3-month intervals for the first 3 years and every 6 months thereafter or until death. The patient history was obtained and a physical examination and nasopharyngoscopy were performed at each follow-up visit. MRI of the head and neck, chest radiography, abdominal sonography, or PET-CT was routinely performed optionally or upon clinical indication of tumor relapse or metastasis.

4. Statistical analysis

Categorical variables were assessed using a chi-square test. The patients were divided into two groups according to the median level of SAA and CRP. The actuarial survival rates were estimated by the Kaplan-Meier method and survival curves were compared using the log-rank test. Multivariate analyses were performed using the Cox proportional hazards model. The covariates included tumour stage, Node stage, sex, SAA, CRP, EBV DNA, age, HBV infection, cardiac disease, diabetes mellitus, family history of NPC, and smok-

Table 1. Relationship between SAA and CRP pretreatment and the clinical characteristics of the 419 NPC patients

Characteristic	SAA (mg/L)			CRP (mg/L)		
	> 4.28 (n=208)	≤ 4.28 (n=211)	p-value	> 1.88 (n=209)	≤ 1.88 (n=210)	p-value
Sex						
Male	166	147	0.017	47	59	0.187
Female	42	64		162	151	
Age (yr)						
≤ 46	112	106	0.460	95	101	0.588
> 46	96	105		114	109	
WHO pathologic classification						
WHO II	5	9	0.290	9	5	0.273
WHO III	203	202		200	205	
ECOG						
0	7	8	0.350	5	10	0.089
1	199	203		202	200	
2	2	0		2	0	
Tumour stage						
T1-2	45	45	0.939	31	59	0.001
T3-4	163	166		178	151	
Node stage						
N0-1	96	134	< 0.001	99	131	0.002
N2-3	112	77		110	79	
Clinical stage						
Stage I	6	4	0.018	3	7	0.001
Stage II	14	24		11	27	
Stage III	110	125		114	121	
Stage IVa	48	43		54	37	
Stage IVb	30	15		27	18	
Treatment						
Radiotherapy	20	30	0.147	19	31	0.074
Chemotherapy+radiotherapy	188	181		190	179	
Radiotherapy						
2DRT/3DCRT	69	57	0.170	68	58	0.273
IMRT	139	154		141	152	
Smoking						
No	132	138	0.678	131	139	0.453
Yes	76	73		78	71	
Chronic HBV infection						
No	192	199	0.412	199	192	0.121
Yes	16	12		10	18	
Cardiac disease						
No	189	198	0.252	193	194	0.989
Yes	19	13		16	16	
Diabetes mellitus						
No	204	204	0.372	205	203	0.364
Yes	4	7		4	7	
Family history of NPC						
No	185	189	0.835	189	185	0.441
Yes	23	22		20	25	

(Continued to the next page)

Table 1. Continued

Characteristic	SAA (mg/L)			CRP (mg/L)		
	> 4.28 (n=208)	≤ 4.28 (n=211)	p-value	> 1.88 (n=209)	≤ 1.88 (n=210)	p-value
EBV DNA (copy/mL)						
< 1,500	77	111	0.001	81	107	0.012
≥ 1,500	131	100		123	103	
Local-regional relapse						
No	184	197	0.081	191	190	0.746
Yes	24	14		18	20	
Distant metastasis						
No	159	177	0.056	157	179	0.009
Yes	49	34		52	31	
Deaths						
No	180	198	0.012	184	194	0.135
Yes	28	13		25	16	

SAA, serum amyloid A; CRP, C-reactive protein; NPC, nasopharyngeal carcinoma; WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group; 2DRT, two-dimensional radiotherapy; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HBV, hepatitis B virus; EBV, Epstein-Barr virus.

ing. All of the reported probability values were two-tailed, with $p < 0.05$ considered to be significant. Statistical analyses were performed using SPSS ver. 20.0 (IBM Corp., Armonk, NY).

5. Ethical statement

All patients provided written informed consent. The study was approved by Sun Yat-Sen University's independent ethics committees.

Results

1. Clinical outcomes

All of the 419 patients had a follow-up examination from their first visit (median, 56.7 months). During the follow-up period, 83 (19.8%) patients developed distant metastasis, 38 patients (9.07%) developed local-regional recurrence, and four patients (0.95%) developed both distant metastasis and local-regional recurrence. These patients almost received palliative chemotherapy or radiotherapy. A total of 36 patients (8.5%) with recurrent or metastasis disease died during our follow-up. Another five patients died without recurrent disease—two patients died of a heart attack, and three patients died of radiotherapy complication. The PFS, OS, DMFS, and

LRFS for all 419 patients were 69.2%, 84.4%, 78.5%, and 89.6%, respectively.

2. Relationship between the SAA or CRP levels and the clinical characteristics of NPC

The median concentration of SAA in the 419 NPC patients was 4.28 mg/L (range, 0.90 to 743.00 mg/L). The median concentration of CRP in the 419 NPC patients was 1.88 mg/L (range, 0.11 to 126.56 mg/L). With this cut-off point of the median concentration, these patients were divided into two groups: the high SAA level group (SAA > 4.28 mg/L) and the low SAA level group (SAA ≤ 4.28 mg/L); the high CRP level group (CRP > 1.88 mg/L) and the low CRP level group (CRP ≤ 1.88 mg/L).

The chi-squared test results showed that our data was relatively balanced. In the results of SAA, regarding age, pathologic classification, ECOG performance, tumour classification, treatment, radiotherapy, smoking, chronic HBV infection, cardiac disease, diabetes mellitus, family history of NPC, local recurrence and posttreatment distant metastasis, the SAA level was not significantly different ($p > 0.05$). However, high level of SAA is associated with risk stratification and poor prognosis of NPC, and the SAA level was significantly associated with node metastasis ($p < 0.001$), clinical staging (p=0.018), EBV DNA (p=0.001), and death (p=0.012). In the results of CRP, similar to those of SAA, CRP was not related to the patient's general condition and inflammatory factors. At the same time, the CRP level was significantly

Fig. 2. Kaplan-Meier curves of progression-free survival according to different groups in 419 NPC patients. (A) Low-SAA (SAA ≤ 4.28 mg/L) and high-SAA (SAA > 4.28 mg/L) group. (B) Low-CRP (CRP ≤ 1.88 mg/L) and high-CRP (CRP > 1.88 mg/L) group. (C) Low-SAA & CRP (SAA ≤ 4.28 mg/L and CRP ≤ 1.88 mg/L) and high-SAA & CRP (SAA > 4.28 mg/L or CRP > 1.88 mg/L) group. (D) Low-EBV DNA (EBV DNA < 1,500 copies/mL) and high-EBV DNA (EBV DNA ≥ 1,500 copies/mL) group. NPC, nasopharyngeal carcinoma; SAA, serum amyloid A; CRP, C-reactive protein; EBV, Epstein-Barr virus.

associated with stage and prognosis, including tumour stage (p=0.001), node classification (p=0.002), clinical staging (p= 0.001), EBV DNA (p=0.012), and distant metastasis (p=0.009) (Table 1).

3. Survival analysis divided by SAA, CRP, integrating SAA & CRP, and EBV DNA

According to high or low level of SAA, or CRP, or integrating SAA & CRP, or EBV DNA, we divided all 419 patients to two groups and analysis their different survival prognosis.

Table 2. Five-year survival rate in the 419 NPC with high or low SAA, CRP, and EBV

Factor	PFS		OS		DMFS		LRFS	
	Percentage	p-value	Percentage	p-value	Percentage	p-value	Percentage	p-value
SAA (mg/L)								
> 4.28	64.5	0.013	79.5	0.025	75.0	0.069	87.8	0.080
≤ 4.28	73.1		91.0		82.0		90.5	
CRP (mg/L)								
> 1.88	65.2	0.064	82.8	0.060	72.3	0.009	91.0	0.826
≤ 1.88	73.3		86.7		84.5		88.3	
SAA and CRP (mg/L)								
SAA > 4.28 or CRP > 1.88	65.2	0.004	81.2	0.037	74.7	0.016	88.8	0.091
SAA ≤ 4.28 and CRP ≤ 1.88	75.9		91.8		86.0		89.5	
EBV DNA (copy/mL)								
≥ 1,500	62.2	0.000	80.5	0.015	72.4	0.000	87.7	0.035
< 1,500	77.8		90.0		85.8		91.8	

NPC, nasopharyngeal carcinoma; SAA, serum amyloid A; CRP, C-reactive protein; EBV, Epstein-Barr virus; PFS, progression-free survival; OS, overall survival; DMFS, distant metastasis-free survival; LRFS, locoregional relapse-free survival.

The split point of SAA (4.28 mg/L) and CRP (1.88 mg/L) were applied the median concentration as before, and the split point of EBV DNA was applied in 1,500 copies/mL approved to be an accurate prognostic value in previous study [5]. The results showed that the high level of EBV DNA had worse prognosis than high level of SAA, CRP, integrating SAA & CRP in the 5-year PFS, OS, DMFS, and LRFS.

Regarding the 5-year PFS rate, the high and low SAA groups showed rate of 64.5% and 73.1%, respectively (p=0.013) (Fig. 2A); the high and low CRP groups showed rate of 65.2% and 73.3%, respectively (p=0.064) (Fig. 2B); the integrating SAA & CRP (high group, SAA > 4.28 mg/L or CRP > 1.88 mg/L; low group, SAA ≤ 4.28 mg/L and CRP ≤ 1.88 mg/L) showed rate of 65.2% and 75.9%, respectively (p=0.004) (Fig. 2C); the high EBV DNA (≥ 1,500 copies/mL) and low EBV DNA (< 1,500 copies/mL) group showed rate of 62.2% and 77.8%, respectively (p < 0.001) (Fig. 2D). All the results above showed that the 5-year PFS of patients with high level of EBV DNA were significantly lower than those with high levels of SAA, or CRP, or integrating SAA & CRP and EBV DNA had a more favorable prognostic value in NPC patients (Table 2, Fig. 2).

Similar to 5-year PFS, the other survival analysis, including 5-year OS, DMFS, and LRFS, we concluded the following results: EBV DNA has a more sensitive predictive p-value than SAA, CRP, and integrating SAA & CRP. The p-value in 5-year OS divided by SAA, CRP, integrating SAA & CRP, and EBV DNA were p=0.025, p=0.060, p=0.037, and p=0.015, respectively. The p-value in 5-year DMFS divided by SAA, CRP, integrating SAA & CRP, and EBV DNA were p=0.069,

p=0.009, p=0.016, and p=0.000, respectively. The p-value in 5-year LRFS divided by SAA, CRP, integrating SAA & CRP, and EBV DNA were p=0.080, p=0.826, p=0.091, and p=0.035, respectively. Integrating SAA & CRP could improve the predictive ability of survival prognosis value to some extent, especially in the 5-year PFS (Table 2).

4. Univariate analysis and multifactorial Cox risk model analysis

The variable in univariate analysis was age (> 46 years vs. ≤ 46 years), sex (male vs. female), smoking (yes vs. no), chronic HBV infection (yes vs. no), diabetes mellitus (yes vs. no), cardiac disease (yes vs. no), family history of NPC (yes vs. no), tumour stage (T1+T2 vs. T3+T4), node stage (N0+N1 vs. N2+N3), SAA level (> 4.28 mg/L vs. ≤ 4.28 mg/L), CRP level (> 1.88 mg/L vs. ≤ 1.88 mg/L), and EBV-DNA (≥ 1,500 copies/mL vs. < 1,500 copies/mL), respectively. In univariate analysis, the significant factors included in the PFS: tumour stage (hazard ratio [HR], 2.048; 95% confidence interval [CI], 1.190 to 3.523; p=0.010), node stage (HR, 1.864; 95% CI, 1.291 to 2.649; p=0.001), SAA (HR, 1.593; 95% CI, 1.100 to 2.305; p=0.014), and EBV DNA (HR, 2.260; 95% CI, 1.521 to 3.358; p=0.000). In univariate analysis, the significant factors included in the OS: node stage (HR, 3.438; 95% CI, 1.711 to 6.910; p=0.001), SAA (HR, 2.095; 95% CI, 1.083 to 4.050; p=0.028), and EBV DNA (HR, 2.308; 95% CI, 1.156 to 4.610; p=0.018) (Table 3).

The association analyses of variables above with PFS and OS were performed using multifactorial Cox regression

Table 3. Multivariate Cox proportional hazards analysis of 419 patients with NPC

Variable	Univariate analysis			Multivariate analysis		
	HR[a]	95% CI	p-value[a]	HR[a]	95% CI	p-value[a]
PFS						
Sex	1.504	0.946-2.392	0.085	-	-	-
Age	0.874	0.608-1.256	0.468	-	-	-
Smoking	1.429	0.991-2.062	0.056	-	-	-
Chronic HBV infection	1.037	0.874-1.229	0.679	-	-	-
Cardiac disease	0.971	0.473-1.991	0.935	-	-	-
Diabetes mellitus	0.908	0.781-1.057	0.213	-	-	-
Family history of NPC	1.142	0.653-1.998	0.641	-	-	-
Tumour stage	2.048	1.190-3.523	0.010	1.903	1.100-3.290	0.021
Node stage	1.864	1.291-2.694	0.001	1.498	1.002-2.241	0.049
SAA	1.593	1.100-2.305	0.014	-	-	-
CRP	1.414	0.979-2.038	0.065	-	-	-
EBV DNA	2.260	1.521-3.358	0.000	1.788	1.157-2.764	0.009
OS						
Sex	1.310	0.604-2.841	0.495	-	-	-
Age	1.055	0.570-1.954	0.864	-	-	-
Smoking	1.172	0.625-2.197	0.620	-	-	-
Chronic HBV infection	1.106	0.854-1.433	0.444	-	-	-
Cardiac disease	2.163	0.841-5.568	0.110	-	-	-
Diabetes mellitus	1.008	0.865-1.174	0.923	-	-	-
Family history of NPC	1.123	0.439-2.870	0.809	-	-	-
Tumour stage	1.328	0.608-2.901	0.476	-	-	-
Node stage	3.438	1.711-6.910	0.001	3.438	1.711-6.910	0.001
SAA	2.095	1.083-4.050	0.028	-	-	-
CRP	1.818	0.967-3.420	0.064	-	-	-
EBV DNA	2.308	1.156-4.610	0.018	-	-	-

NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; HBV, hepatitis B virus; SAA, serum amyloid A; CRP, C-reactive protein; EBV, Epstein-Barr virus; OS, overall survival. [a]We calculated hazard ratios and p-values with an adjusted multivariate Cox proportional hazards regression model, including sex (male vs. female), age (> 46 years vs. ≤ 46 years), smoking (yes vs. no), chronic hepatitis B virus infection (yes vs. no), cardiac disease (yes vs. no), diabetes mellitus (yes vs. no), family history of nasopharyngeal carcinoma (yes vs. no), tumour stage (T1+T2 vs. T3+T4), node stage (N0+N1 vs. N2+N3), SAA level (> 4.28 mg/L vs. ≤ 4.28 mg/L), CRP level (> 1.88 mg/L vs. ≤ 1.88 mg/L), and EBV-DNA (≥ 1,500 copies/mL vs. < 1,500 copies/mL) as covariates. We selected variables with the forward stepwise approach. Only variables that were significantly associated with survival are presented.

analyses. The analyses demonstrated that the tumour stage (HR, 1.903; 95% CI, 1.100 to 3.290; p=0.021), node stage (HR, 1.498; 95% CI, 1.002 to 2.241; p=0.049), and EBV DNA (HR, 1.788; 95% CI, 1.157 to 2.764; p=0.009) were independent predictors of PFS. The node stage (HR, 3.438; 95% CI, 1.711 to 6.910; p=0.001) was independent predictors of OS in patients with NPC (Table 3). SAA was not an independent prognostic factor in multivariate analysis, although it was significant in univariate analysis.

Discussion

SAA and CRP are acute-phase proteins and have been demonstrated to be contributors to cancer development and progression. SAA and CRP are regulated by related cytokines, and the amplitude of the inflammation-related increase in SAA is similar to, or slightly greater than, that of CRP [16]. However, the physiologic level of circulating SAA is approximately 10-fold greater than that of CRP, suggesting that SAA may be more useful for detecting slight elevations

in systemic or chronic inflammation [16,17]. Several previous and recent studies have proposed a direct correlation between the SAA concentrations and tumour grade [18,19]. Additionally, SAA has been reported to be a marker of disease progression in different malignancies, including renal cell carcinoma [20,21], lung [22,23], colorectal [24], uterine serous papillary cancer [25], and breast cancer [12]. Some research demonstrated that SAA was potential NPC metastasis-specific serum biomarkers [11] and SAA could be a useful biomarker to monitor relapse of NPC [9]. Regarding CRP, a retrospective study [14] showed that baseline CRP may be useful to predict the prognosis of metastatic NPC patients. Previous we have found that baseline plasma EBV DNA and CRP levels were significantly correlated with survival in NPC patients [13]. A study suggested that systemic inflammation, as measured by circulating CRP and SAA, may be an important long term prognostic factor for breast cancer and elevated SAA and CRP were associated with reduced OS [12]. However, a prospective study to validate this prognostic effect of SAA and CRP in NPC is still needed. Quantification of plasma EBV DNA is useful for monitoring patients with NPC and predicting the outcome of treatment [5]. Pretherapy circulating EBV DNA load is an independent prognostic factor to Union for International Cancer Control staging in NPC [26]. It is very necessary to use a prospective approach to verify the previous reports about SAA and CRP in the predictive function of prognosis in NPC, and compare the effect of EBV DNA.

The advantage of this study is its prospective design and analysis of pretreatment blood samples. In this study of 419 non-metastatic primary NPC patients, the chi-squared test results showed that the level of SAA and CRP were not related to the patient's general condition and inflammatory factors, but significantly associated with stage and prognosis, including tumour stage or Node classification or clinical staging or distant metastasis or death or the EBV DNA. We deserve further study that which factors predict prognosis is more important, the staging, the EBV DNA, or the inflammatory factors SAA and CRP.

In this study, we found significant associations of higher levels of SAA (64.5% vs. 73.1%, p=0.013) reduced 5-year PFS, but the result of CRP was close to be significant (65.2% vs. 73.3%, p=0.064). Additionally, we observed that the integrating SAA & CRP improved the ability to predict prognosis and high level of circulating SAA combined with CRP was significantly correlated with survival in NPC patients (65.2% vs. 75.9%, p=0.004), a finding that was similar to that in patients with other cancers, including breast cancer [12], melanoma [27] and colorectal cancer [24]. On the other hand, EBV DNA detection showed a superior predictive result, the 5-year PFS in the EBV DNA ≥ 1500 copies/mL group was obviously different than the EBV DNA < 1,500 copies/mL

group (62.2% vs. 77.8%, p < 0.001). At the same time, in the 5-year OS (p=0.015), DMFS (p=0.000), LRFS (p=0.035), the high level of EBV DNA was also significant different than low level of EBV DNA. Although SAA was significant in univariate analysis, it was not an independent prognostic factor in multivariate analysis. Multifactorial Cox regression analysis confirmed that in the PFS, the independent prognostic factors were including EBV DNA (HR, 1.788; p=0.009), tumour stage (HR, 1.903; p=0.021) and node stage (HR, 1.498; p=0.049), but the SAA and CRP were not included in the independent prognostic factors. The above results showed that the EBV DNA, which is the best biomarker so far, was more sensitive to the prediction of NPC than the inflammatory factors SAA and CRP. High level of EBV DNA, SAA, and CRP were both poor prognostic factors for NPC patients, especially EBV DNA. For these patients, we can consider performing closer follow-ups and early intervention.

SAA and CRP are acute-phase proteins and have been demonstrated to be connected with the Inflammation related diseases [6,7], such as chronic HBV infection, diabetes mellitus and cardiac disease. In this study, the chi-square test results showed that the level of SAA and CRP were not related to these diseases. Also, the association analyses of chronic HBV infection, diabetes mellitus, and cardiac disease were not independent predictors of PFS and OS in NPC patients with multifactorial Cox regression analyses. Although SAA and CRP were associated with a self-reported history of myocardial infarction and history of heart failure in the HEAL study [28]. In our study, two patients died of a heart attack, which was a low-probability event here. Thus, our results suggested that survival prognosis of patients with NPC were not related to these pretreatment inflammatory diseases.

The drawback of our study is that the data were obtained exclusively from one centre. Although our cancer centre treats many NPC patients, these results also need to be validated in other data sets. The second limitation is that the single pretreatment measurement of SAA, CRP, and EBV DNA. A single measurement is likely to underestimate the magnitude of the association between the biomarkers and survival. One strength of our study is the reliable measurement of both the SAA and CRP levels with a high accuracy in a core laboratory. And the other is the large size examination should perform throughout the treatment period, including pretreatment, post-treatment, and follow-up periods.

In summary, this study suggests that pretreatment SAA and CRP had a certain relationship with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP were poor. However, the predictive ability of SAA and CRP was worse than that of EBV DNA. These results also need to be validated with further large collaborative studies.

In conclusion, there is a certain relationship between SAA and CRP with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP are poor. However, the predictive ability of SAA and CRP is worse than that of EBV DNA.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Author Details

[1]Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, [2]Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, [3]Department of Oncology, the First Affiliated Hospital, Jinan University, Guangzhou, [4]Department of Information Technology, Sun Yat-Sen University Cancer Center, Guangzhou, China

References

1. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a "Cantonese cancer"? Chin J Cancer. 2010;29:517-26.
2. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16:645-55.
3. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-54.
4. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-56.
5. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461-70.
6. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7.
7. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 1990;20:129-47.
8. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 2007;14:84-93.
9. Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res. 2004;10(1 Pt 1):43-52.
10. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF Jr. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics. 2003;3:1720-4.
11. Liao Q, Zhao L, Chen X, Deng Y, Ding Y. Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma. Clin Exp Metastasis. 2008;25:465-76.
12. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437-44.
13. Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. Int J Radiat Oncol Biol Phys. 2015;91:

325-36.

14. Xia WX, Ye YF, Lu X, Wang L, Ke LR, Zhang HB, et al. The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy. PLoS One. 2013;8:e76958.

15. An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117: 3750-7.

16. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999;37:381-8.

17. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest. 1996;26:427-35.

18. Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol. 1986;39:794-7.

19. Liu DH, Wang XM, Zhang LJ, Dai SW, Liu LY, Liu JF, et al. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci. 2007;20:33-40.

20. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010;103:101-11.

21. Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, et al. Validation of serum amyloid alpha as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol. 2012;62:685-95.

22. Cho WC, Yip TT, Cheng WW, Au JS. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer. 2010;102:1731-5.

23. Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2011;10:1383-95.

24. Toriola AT, Cheng TY, Neuhouser ML, Wener MH, Zheng Y, Brown E, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer. 2013;132:2648-58.

25. Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, et al. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer. 2009;101:335-41.

26. Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol. 2006;24:5414-8.

27. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol. 2009;27:2199-208.

28. Pierce BL, Neuhouser ML, Wener MH, Bernstein L, Baumgartner RN, Ballard-Barbash R, et al. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat. 2009;114: 155-67.